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The (pro)renin receptor (PRR) is a newly reported member of the renin-angiotensin system
(RAS); a hormonal cascade responsible for regulating blood pressure. Originally, identifica-
tion of PRR was heralded as the next drug target of the RAS, of which such therapies would
have increased benefits against target-organ damage and hypertension. However, in the
years since its discovery, several conditional knockout mouse models of PRR have demon-
strated an essential role for this receptor unrelated to the RAS and blood pressure. Specific
deletion of PRR in podocytes or cardiomyocytes resulted in the rapid onset of organ failure
and subsequently animal mortality after only a matter of weeks. In both cell types, loss of
PRR resulted in the intracellular accumulation of autophagosomes and misfolded proteins,
indicating a disturbance in autophagy. In light of the fact that the majority of PRR is located
intracellularly, this molecular function appears to be more relevant than its ability to bind
to high, non-physiological concentrations of (pro)renin.This review will focus on the role of
PRR in autophagy and its importance in maintaining cellular homeostasis. Understanding
the link between PRR, autophagy and how its loss results in cell death will be essential for
deciphering its role in physiology and pathology.
Keywords: renin-angiotensin system, cardiovascular disease, Wnt signaling, vacuolar H+-ATPase, proteostasis,
autophagosome, rapamycin
PRR AND THE RENIN-ANGIOTENSIN SYSTEM
The discovery of the (pro)renin receptor (PRR) by Ngyuen et al.
(1) came at a time in the field of hypertension and cardiovascular
disease when the search was on for a new therapeutic target of
the renin-angiotensin-system (RAS). Normally, this hormone sys-
tem is responsible for the regulation of blood pressure and water
retention. Under pathological conditions, overactivity of the RAS
results in the downstream accumulation of angiotensin (ang) II,
an octapeptide which binds to specific receptors in target organs
such as the kidney and heart. Pathologically high levels of ang
II leads to hypertension and injury to target organs, resulting in
disease (2). Numerous therapeutic interventions currently in use
considerably reduce levels of ang II and are effective at lowering
blood pressure (3). However, these drugs are not completely pro-
tective against target-organ damage,and as such, there is continued
interest in the development of therapeutics against other compo-
nents of the RAS which may have increased protection against
disease.
The RAS is classically initiated by the proteolytic removal of the
prosegment of prorenin to form active renin. Renin then starts the
RAS cascade by cleaving angiotensinogen to form the decapep-
tide angiotensin I, which is further cleaved by the angiotensin-
converting enzyme to form ang II. Upon discovery of PRR, an
additional non-classical activation of prorenin was identified.
Here, upon binding PRR, a conformational change in prorenin
is thought to be induced, resulting in the removal of the prorenin
prosegment from the active enzymatic cleft and hence, the non-
proteolytic activation of prorenin into renin and initiation of the
RAS cascade (1). This was the first study to show a molecular
function for PRR and demonstrate its putative role in activation
of the RAS. It should be noted however that the concentrations of
prorenin used to observe this effect are considerably higher than
those levels detected in vivo (4).
In addition to the activation of the RAS and generation of ang
II, an alternative mechanism was proposed by which (pro)renin
binding to the PRR directly contributes to disease. Human mesan-
gial cells treated in vitro with recombinant human or rat renin
showed an increase in transforming growth factor (TGF)-β and
plasminogen activator inhibitor (PAI)-1 levels. In the presence
of an ang II receptor blocker (ARB), the increase of TGF-β and
PAI-1 was not affected, indicating that this result was indepen-
dent of the RAS and ang II generation (5). In a human monocyte
cell line, stimulation with recombinant renin in the presence of an
ARB resulted in an activation of extracellular signal-related kinases
(ERK) 1/2 (6). This again suggested that the increase in phospho-
ERK 1/2 is directly due to the binding of prorenin to the PRR, and
unrelated to the initiation of the RAS. Several other studies have
also shown the activation of signaling pathways upon (pro)renin
stimulation in an ang II independent manner (7–9). The identifi-
cation of this second function for PRR led to the hypothesis that
(pro)renin binding to the PRR causes pathology independently
of the RAS via the induction of inflammatory and pro-fibrotic
signaling cascades.
A MURKY PICTURE OF PRR FUNCTION EMERGES
THERAPEUTIC BLOCKADE OF PRR PREVENTS TARGET-ORGAN
DAMAGE?
The aforementioned studies laid the framework for the develop-
ment of inhibitors of PRR. To date, only one putative inhibitor
of PRR has been published: the handle-region peptide (HRP).
HRP is a short pentapeptide comprised from the prorenin
prosegment (11P–15P). This putative inhibitor was developed
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by Suzuki et al. who screened antibodies raised against vari-
ous epitopes of prorenin that would induce the non-proteolytic
activation of prorenin (10). They identified two regions of
prorenin, the “handle” (11P–15P) and “gate” (15P–26R) from
which they deduced that these two regions are most impor-
tant in the non-proteolytic activation of prorenin. The “handle”
region was decided by the authors to be the most exposed epi-
tope of prorenin and thus more likely to directly interact with
PRR (10).
Administration of this peptide in vivo showed protection in
several animal models of disease, specifically in diabetic microvas-
cular complications (8, 11–13) and in a rat model of spontaneous
hypertension (14). The authors did not identify a precise concen-
tration at which HRP was most effective. Several other groups
attempted to reproduce these studies however they were unable
to show any efficacy (6, 15–17). A study by Wilkinson-Berka et al.
developed a sensitive radioimmunoassay to detect plasma levels
of HRP. These authors were not able to detect HRP in the plasma
of SD rats infused with 1 mg/kg/day of HRP by mini-pump for
7 days, indicating the rapid metabolism of the peptide (13). This
raises the question as to whether HRP is able to effectively traffic
through the body to specifically inhibit PRR at the target-organ of
interest.
It is important to note that HRP was developed at a time in
which high-resolution structural information on prorenin was not
known. Morales et al. have since solved the structure of prorenin
and provide some explanation for the discrepancy between the
various HRP studies (18). Based on their structural information,
they show that the “handle” region is not an exposed epitope,
as originally thought, but instead buried in the prorenin mole-
cule. This is supported by a recent study which has shown that
HRP does not specifically bind PRR with high affinity (19). This
is in agreement with a study done by us, where we demonstrate
non-specific binding of fluorescently labeled HRP to cells lacking
PRR (15).
OVEREXPRESSION OF PRR LEADS TO HYPERTENSION?
As described above, the contribution of PRR to cardiovascu-
lar disease and hypertension was hypothesized to be due to the
binding of prorenin to PRR, resulting in its non-proteolytic acti-
vation and/or the induction of signaling pathways which directly
lead to pathology. The development of transgenic animal mod-
els over-expressing PRR were expected to shed more light on
this, as with more PRR available it was hypothesized that more
binding of (pro)renin would occur and thus more of these
pathogenic processes would occur. Unfortunately, these animal
models did not give a clear indication as to the molecular con-
tribution of PRR to cardiovascular disease. Rats constitutively
over-expressing human PRR had normal blood pressure and ang
II levels but developed renal nephropathy (20). In contrast, in
a different model in which transgenic rats overexpressed PRR
solely in smooth muscle cells, these animals had elevated sys-
tolic blood pressure but normal renal function (21). The differing
results from these two models have been proposed to be due to
differences in the uncontrolled overexpression of PRR in these
animals (22).
GENETIC ABLATION OF PRR PREVENTS HYPERTENSION AND
CARDIOVASCULAR DISEASE?
In consideration of the confusing results from the overexpression
models and HRP studies, the field next turned to the development
of knockout models to establish if loss of PRR would be protec-
tive against cardiovascular disease. The first attempt at generation
of a PRR knockout mouse model was a failure. Injection of PRR
knockout embryonic stem cells into host blastocysts did not gen-
erate chimeras, indicating an essential function of PRR in cellular
development and survival (23). This is in contrast to other mem-
bers of the RAS in which knockout mice have been successfully
generated (24). Also of note is that renin expression begins well
after PRR [in the mouse not until E14 (25)], again implying a
non-RAS role for PRR. It is important to note here that when
PRR was first discovered by Nguyen et al. it was shown to be
identical to that of a protein called M8–9, a truncated protein
of the vacuolar H+-ATPase (V-ATPase) (1). As the V-ATPase is
a multifunctional protein essential for cellular homeostasis and
development (26), these initial PRR knockout reports gave great
support to the notion that PRR has functions separate to the RAS.
Several other animal models have confirmed that loss of PRR has
a profound effect on development, including zebrafish (27), Xeno-
pus (28, 29), and Drosophila (28, 30). PRR also appears to be
important for human development, as it has been identified that
humans with mutations in PRR have intellectual disabilities and
epilepsy (31). However, this singular study needs to be reassessed
and validated in light of the information now available from whole
genome sequencing (32).
Due to the developmental effects described for PRR, an alterna-
tive approach at understanding the role of PRR in cardiovascular
disease was undertaken by Kinouchi et al. (33). Here, a conditional
knockout model was generated in which PRR was specifically
deleted in cardiomyocytes (ATP6AP2lox/Y; αMHC-Cre). These
mice had a severe cardiac phenotype and died only 3 weeks after
birth. Upon closer inspection of the PRR knockout cardiomy-
ocytes, an accumulation of vesicular bodies was observed. Addi-
tionally, autophagosomes comprising of electron dense material
were evident. By western blotting the authors show an accumula-
tion of LC3B II and p62 in myocardial tissue from PRR knockout
mice, indicating a disturbance in autophagic flux (33). In terms
of the original question posed, this study did not give any insight
as to how the binding of (pro)renin to PRR may contribute to
cardiovascular disease. More recently, we and another group have
generated podocyte-specific PRR knockout mice (ATP6AP2lox/Y;
Podocin-Cre) (34, 35). In these two studies, knockout mice had
again severe phenotypes and mortality after only 3 weeks. Simi-
larly to PRR knockout in cardiomyocytes, the study by our group
also detected autophagosomes within these podocytes and iden-
tified alterations in levels of LC3B (35), confirming loss of PRR
disturbs autophagic flux.
In summary, in the 11 years since its discovery the contribution
of PRR to the pathogenesis of cardiovascular disease and hyper-
tension remains unclear. However, one clear and striking result
from the above-mentioned conditional knockout studies in car-
diomyocytes and podocytes is that the loss of PRR results in a
disturbance in cellular autophagic flux and homeostasis (33–35).
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This is in addition to knockout models in other organisms where
the loss of PRR disturbs cellular function and development. This is
confirmed by the description of new tissue-specific PRR knockout
model (ATP6AP2lox/Y; Hoxb7-Cre), which also has severe devel-
opmental effects (36). Taken together, the regulation of autophagy
and cellular homeostasis is thus looking more likely to be the true
cellular function of PRR and is the focus of this review.
AUTOPHAGY
Autophagy is derived from the Greek names of auto “self” and
phagein “to eat,”and describes the process by which the cell literally
eats itself. This is an essential and evolutionary conserved process
utilized by all cell types to maintain cell homeostasis. Under nor-
mal conditions, a basal level of autophagy is required to maintain
protein quality control and remove damaged proteins, organelles,
and lipids, which may otherwise harm normal cellular function
(37). With aging, the rate of basal autophagy is thought to decline
and it has been proposed that this reduction in autophagic flux
results in the accumulation of damaged proteins and the induc-
tion of neurodegenerative and cardiovascular diseases (38, 39).
The level of basal autophagy has been shown to vary between dif-
ferent cell types with terminally differentiated cell types, such as
neurons, having very high levels of autophagic flux (40).
Autophagy also has an essential role in response to conditions
of cellular nutrient deprivation or starvation. Under these con-
ditions, macroautophagy (hereafter referred to as autophagy) is
induced as a way in which to replenish nutrients and prevent cell
death, via the degradation of cellular proteins and organelles to
generate amino acids. Due to its important role in maintaining
cellular homeostasis the process of autophagy is extremely tightly
regulated. This process involves multiple steps and the converging
of several signaling pathways, requiring the coordinated action of
literally hundreds of proteins. The specific details involved in the
regulation, initiation, action, and resolvement of autophagy have
been discussed extensively elsewhere (41, 42). For the purpose of
this review, a brief summary is shown in Figure 1.
The induction of autophagy is controlled by an atypical serine
kinase, the mammalian target of rapamycin (mTOR). Under nor-
mal conditions, where the cell is in a nutrient rich state or with
a lack of stress signals, mTOR is active and inhibits autophagy.
However, once in a nutrient-deprived or stressed state, the activity
of mTOR is reduced/inhibited, and the process of autophagy is
initiated.
Briefly, autophagy begins with the nucleation of the autophago-
some membrane. Upon a decrease in mTOR activity, the
autophagy-related protein (Atg) 13 is dephosphorylated, allow-
ing it to form an activating complex with another “Atg” pro-
tein, Atg1. The assembly of this complex initiates the forma-
tion of the autophagosome membrane, driven by Beclin-1 and a
phophoinositide-3 kinase (PI3K) complex (Figure 1). The mem-
brane is then extended around the contents to be degraded. The
extension of this membrane involves numerous other Atg proteins
but the most important, due to its common use in histology and
western blotting to detect autophagy, is the protein light-chain
(LC) 3B (in yeast known as Atg8). LC3B is normally present in
the cytoplasm (LC3B I) and it is only upon its post-translational
modification, where a lipid group (phosphatidylethanolamine)
FIGURE 1 | A brief schematic of the regulatory processes involved in
autophagy (see text for detail). Also shown is our hypothesized
mechanism by which knockout of PRR/ATP6AP2 results in a loss of mTOR
activity and the induction of autophagy.
is added (LC3B II) that it associates with the membrane of the
autophagosome. This modification is commonly used as a marker
for autophagy as the more hydrophobic LC3B II runs at a dif-
ferent molecular weight than LC3B I when analyzed by western
blotting (43, 44). When the cellular contents to be degraded
are completely enclosed by the autophagosome, the next step of
autophagy involves the fusion of this body with a lysosome; thus
forming an autophagolysosome. The lysosome is comprised of
various proteases which require acidic pH for their activity. This
pH is provided by the activity of the vacuolar H+-ATPase (V-
ATPase; discussed further in the next section). After degradation of
its contents and the release of amino acids, the autophagolysosome
separates and autophagy is attenuated. Importantly, the separa-
tion and maturation of lysosomes back to their normal state
has been shown to also be regulated by mTOR (Figure 1) (45).
Thus an important self-regulatory negative feedback mechanism
is established in which after the restoration of cellular nutrients,
mTOR is reactivated and both inhibits the induction of further
autophagy and is involved in the resolvement of cellular home-
ostasis, via the removal of autophagosomes from the cell and
promoting the maturation of lysosomes and return to their normal
morphology (45).
Modulation of autophagy regulatory networks can have many
different effects, depending on the level at which the autophagy
pathway is inhibited, the cell type and/or disease in question in
which such a modulation is utilized. Rapamycin is a chemical
derived from S. hygroscopicus and is a potent inhibitor of mTOR
activity and thus is an inducer of autophagy (46). Incubation of a
number of different cell types with rapamycin results in the induc-
tion of autophagy and eventual death, due to a failure of the cells
to attenuate and resolve autophagy (47–51). However, in some sit-
uations this can be of benefit. Rapamycin is currently approved
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for clinical use to treat certain types of cancers such as breast, col-
orectal, and renal. Here, rapamycin potently inhibits cancer cell
proliferation and is able to induce the death of cancerous cells
and even inhibit angiogenesis (52). However rapamycin is not an
effective drug for all clinical situations, as induction of autophagy
can also have detrimental effects to the function of non-diseased
cells (53). Thus for the use and further development of therapeu-
tics such as this, a thorough understanding of the requirements of
different cells for autophagy is crucial.
THE VACUOLAR H+-ATPase AND ITS ROLE IN AUTOPHAGY
The “discovery” of PRR was eventually realized not to be the dis-
covery of a novo protein after all. It is now well established that
PRR is actually ATP6AP2; a gene product identified as an accessory
protein of the V-ATPase (54). PRR has been shown to co-localize
and immunoprecipitate with the V-ATPase, indicating a functional
association (54, 55). In zebrafish, the loss of PRR results in a loss
in pigmentation phenotype which directly mimics that of loss
of a V-ATPase subunit (27). Additionally, the phenotype of the
cardiomyocytes-specific PRR knockout model was attributed by
the authors to a loss of V-ATPase function (33).
The V-ATPase is an essential multi-subunit complex present in
nearly all cell types. It is responsible for establishing and maintain-
ing intracellular pH gradients. Thus, its importance in maintaining
cellular homeostasis is considerable. These duties range from
the acidification of the lysosome, endocytosis, and recycling of
membrane proteins, secretion and processing of hormones such
as insulin, and basic cellular trafficking including the fusion of
vesicular membranes (29, 56, 57).
It has recently been shown that the V-ATPase is impor-
tant for the above-described mTOR signaling pathway, involved
in regulating autophagy (Figure 1) (58). Addition of specific
inhibitors of V-ATPase to the culture media of HEK293 cells
inhibited the activity of mTOR. Additionally, immunoprecipita-
tion studies identified an interaction between V-ATPase subunits
and the Rag-Regulator complex, which interacts with mTORC1 to
form the active mTOR signaling complex. This study proposed a
mechanism by which the V-ATPase is thus crucial in maintaining
mTOR activity by sensing the nutrient state of the cell and mod-
ulating the interaction between mTORC1 and the Rag-Regulator
complex (58).
An important regulatory network between mTOR and the
expression of V-ATPase subunits has also been identified (59).
In a cell line with a genetically abnormally increased activity of
mTOR, the expression of V-ATPase subunits was also increased.
Of note is that PRR/ATP6AP2 was one such subunit identified
to have increased expression under these circumstances. It was
therefore concluded that mTOR regulates the expression of V-
ATPase subunits (59). Considering the previous study by Zoncu et
al. (58), this results in the development of a positive feedback loop
whereas V-ATPase subunits are essential for maintaining mTOR
activity and vice versa (Figure 1).
PRR: A PROTEIN IMPORTANT FOR REGULATING
AUTOPHAGY?
The best insight into what is the precise contribution of PRR to
autophagy comes from analysis of the recent studies by Riediger
et al. (35) and Oshima et al. (34). These studies both generated
mice with PRR specifically deleted in podocytes; a specialized
cell of the kidney. As mentioned briefly above, loss of PRR in
this cell type resulted in animal mortality approximately 3 weeks
after birth (Table 1) (34, 35). The cause of this severe pheno-
type was due to the animals developing nephritic syndrome and
acute kidney injury; identified by proteinuria, glomerulosclero-
sis, and the accumulation of proteaceous casts in tubules. Upon
inspection by transmission electron microscopy, the accumula-
tion of vesicles was observed in addition to the presence of large
autophagosomes, also after only 3 weeks. Additionally, an accumu-
lation of LC3B was detected, indicating that the deletion of PRR
in podocytes results in a disturbance in autophagic flux (34, 35).
This mirrors what Kinouchi et al. observed in their cardiomyocyte-
specific PRR knockout model, as described above (33). Eventually
this disturbed autophagic flux led to podocyte death, as indicated
by a decrease in Wilms tumor-1 signal (34, 35). This did not cor-
relate with the activation of apoptotic pathways, indicating that
the gross disturbance in autophagy was the main cause of cell
loss (35).
Two separate conditional knockout studies in the podocyte have
been generated to specifically investigate the role of autophagy
in this cell type (Table 1). Atg5 is a protein important for the
elongation of the autophagosome membrane and sequestration
of contents (Figure 1). In contrast to PRR, conditional deletion
of ATG5 in podocytes resulted in severe kidney disease only after
24 months, with no animal mortality at this time (60). The pres-
ence of autophagosomes within Atg5 knockout podocytes was
evident only after 8–10 months (Table 1). In this study, the authors
proposed that loss of Atg5 results in a gradual decrease in the
cells ability to remove unwanted and damaged cellular material
(60). In this case, the late onset of disease can be attributed to the
cells lacking a functioning basal autophagy and so, first a certain
threshold of cellular stress must be reached (i.e., by aging) before
the phenotype is evident.
In clear contrast to this is the study by Cina et al. who gen-
erated podocyte-specific mTOR knockout mice (61). Here, these
mice developed proteinuria, glomerulosclerosis, and other hall-
marks of acute kidney injury after only 3 weeks. Like both the
PRR and ATG5 knockout studies, autophagosomes were detected
within the podocytes, however, more similar to the PRR knockout
model, these were evident after only 2 weeks (Table 1). The authors
propose in this study that the loss of mTOR in podocytes has a
twofold effect (61). Firstly, loss of mTOR results in the induction
of autophagy, as indicated by the presence of autophagosomes and
accumulation of LC3B II. Secondly, the authors demonstrate that
loss of mTOR results in a failure of negative feedback loops to
stop the induction of further autophagy and resolve this process.
Hence, they propose that the severe and acute nephritic syndrome
in mTOR podocyte-specific knockout mice is due to the disruption
of the autophagic cycle at two points: induction and resolvement
(Figure 1).
What is striking is the similarity in the severity of the phe-
notype observed between the conditional knockout of PRR and
mTOR in these podocyte studies (Table 1). This strongly sug-
gests that PRR is important in mTOR function, either due to
a specific interaction or indirectly via its association with the
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Table 1 | Comparison of the time of onset of various parameters in PRR and autophagy-related podocyte-specific knockout mouse models.
(Pro)renin receptor (34, 35) Atg5 (60) mTOR (61)
Genotype ATP6AP2lox/Y; Pod-Cre ATG5flox/flox; Pod-Cre mTORflox/del; Pod-Cre
Mortality 3 weeks No effect (mice live >24 months) Not analyzed
Proteinuria (albumin/creatinine) 2 weeks Mild at 8–12 months, severe at
20–24 months
3 weeks
Glomerulosclerosis 2 weeks 24 months 4 weeks
Proteinaceous casts in tubules 2 weeks 24 months 2–4 weeks
Podocyte number Decreased at 2 weeks Decreased at 22 months Not analyzed
Podocin expression Decreased at 3 weeks (not
analyzed by Riediger et al.)
No change at 24 months Decreased at 3 weeks
Podocyte foot effacement 2 weeks 24 months 3 weeks
Autophagosome formation within podocytes 2 weeks 8–12 months 2 weeks
Alteration in LC3B processing Accumulation of LC3B positive
cells (immunofluorescence)
Not analyzed Increased LC3B II conversion
(western blot)
V-ATPase (58). In support of this concept is that ubiquitous
mTOR knockout mouse models also have similarities to that of
PRR, where mTOR knockout embryonic stem cells have lim-
ited proliferation resulting in early lethality (E5.5), indicating
an essential role for mTOR in cellular development (62, 63).
The comparison of future PRR and mTOR conditional knock-
out models in other cell types will give more insight into the
molecular mechanism by which PRR is important for mTOR
activity.
WHERE TO NEXT?
There is now clear evidence that PRR has an essential role in
maintaining cellular homeostasis, specifically due to its involve-
ment in autophagy. This will undoubtedly result in shift in
research focus away from the contribution of PRR to cardio-
vascular disease, toward understanding its general role in the
biology, homeostasis, proliferation, and development of all cell
types.
It must be acknowledged that this paradigm change was ini-
tiated by the study by Cruciat et al. (29). This group essentially
stumbled across PRR as being important in canonical Wnt signal-
ing as part of their large research study to identify new genes of
importance to this signaling pathway. In this study, they showed a
clear link between the association of PRR with the V-ATPase and
the activation of protein receptors important for the induction
of Wnt signaling (29). It has also been established in Drosophila
that PRR is important for another Wnt signaling pathway, the
planar-cell polarity (PCP) pathway (30). More recently, this group
has dissected the mechanism by which PRR is important for PCP
signaling. Here, loss of PRR affected the co-localization and endo-
cytosis of receptors important for PCP, and resulted in defects in
the degradation of other receptors such as Notch and E-Cadherin
(64). As discussed in this review, it also appears likely that PRR
has an important role in the signaling pathways important for
regulating autophagy. We therefore propose that PRR is essen-
tial for proteostasis, where the loss of this protein results in the
disturbance of multiple signaling pathways, resulting in severe
defects in cellular homeostasis. This could be due to its role in
regulating autophagy, in which loss of PRR results in the dis-
turbance of multiple signaling pathways, due to the induction
of autophagy and lack of resolvement of this process, resulting
in eventual cellular death. It is also possible, as with the study
described by Cruciat et al. that PRR specifically interacts with
proteins important for signal transduction. Of note is that the
signaling pathways of Wnt and autophagy are closely intertwined
(65). Deciding which of these two hypotheses is correct will be
made easier once the precise molecular mechanism by which PRR
contributes to V-ATPase activity is determined. This is a partic-
ularly important concept to understand in light of the fact that
lower organisms which lack PRR (e.g., yeast) still have a function-
ing V-ATPase (33). The answers to these questions will lead to
new insight into the regulatory pathways essential for maintaining
cellular homeostasis.
CONCLUSION
It is now clear that PRR has an important role in the regulation and
maintenance of cellular homeostasis, most probably via signaling
pathways important for autophagy. In consideration of this new
information, it would be interesting to revisit the original studies
describing the involvement of PRR with the RAS and regulation of
blood pressure, to distinguish the role of V-ATPase function, and
autophagy in these systems. More recent papers, which have iden-
tified a role for PRR in various signaling pathways, should also be
carefully re-examined to deduce whether these effects are directly
mediated by PRR, or indirectly by the gross disturbance of cellular
homeostasis.
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